钠-葡萄糖协同转运蛋白2抑制剂对系统性红斑狼疮合并2型糖尿病患者心血管、肾脏事件一级预防的疗效与安全性:基于人群的目标试验模拟
在美国保险数据库中模拟临床试验,比较SGLT2i与DPP4i对合并2型糖尿病的SLE患者心血管、肾脏事件一级预防的效果,经倾向评分匹配各2165例,SGLT2i组急性肾损伤、慢性肾病、终末期肾病、心力衰竭、急诊就诊和严重脓毒症风险显著降低,生殖器感染风险增加,全因死亡、狼疮肾炎、心梗、卒中、住院、尿路感染、糖尿病酮症酸中毒和骨折风险无显著差异。
要点
- SGLT2i组急性肾损伤风险显著低于DPP4i组(HR 0.49,95%CI 0.39-0.63)。
- SGLT2i组心力衰竭风险显著低于DPP4i组(HR 0.72,95%CI 0.56-0.92)。
- SGLT2i组生殖器感染风险显著高于DPP4i组(HR 1.31,95%CI 1.07-1.61)。
核心结论
- 在模拟临床试验中,与DPP4i相比,SGLT2i治疗与合并SLE和T2D患者多种心肾并发症风险显著降低相关。
研究设计与样本
- 基于美国保险数据库的模拟临床试验,评估SGLT2i对比DPP4i在合并SLE和T2D患者中对心血管、肾脏及其他临床结局的一级预防作用。
- SGLT2i起始者基于临床和人口学因素通过倾向评分与DPP4i起始者匹配,使用Cox模型计算风险比(HR)及95%置信区间(CI)。
- 共比较2165例起始SGLT2i患者与2165例倾向评分匹配的起始DPP4i患者,平均随访753.1(±479.2)天。
主要发现
- SGLT2i组急性肾损伤风险显著低于DPP4i组(HR 0.49,95%CI 0.39-0.63)。
- SGLT2i组慢性肾病风险显著低于DPP4i组(HR 0.61,95%CI 0.50-0.76)。
- SGLT2i组终末期肾病风险显著低于DPP4i组(HR 0.40,95%CI 0.20-0.80)。
- SGLT2i组心力衰竭风险显著低于DPP4i组(HR 0.72,95%CI 0.56-0.92)。
- SGLT2i组急诊就诊风险显著低于DPP4i组(HR 0.90,95%CI 0.82-0.99)。
关键数值与推荐
- SGLT2i组严重脓毒症风险显著低于DPP4i组(HR 0.61,95%CI 0.39-0.94)。
- SGLT2i组全因死亡风险与DPP4i组无显著差异(HR 0.89,95%CI 0.65-1.21)。
- SGLT2i组狼疮肾炎风险与DPP4i组无显著差异(HR 0.67,95%CI 0.38-1.15)。
- SGLT2i组心肌梗死风险与DPP4i组无显著差异(HR 0.81,95%CI 0.54-1.23),卒中风险无显著差异(HR 1.03,95%CI 0.74-1.44)。
- SGLT2i组住院风险与DPP4i组无显著差异(HR 0.76,95%CI 0.51-1.12)。
临床怎么用
- SGLT2i组生殖器感染风险显著高于DPP4i组(HR 1.31,95%CI 1.07-1.61)。
- SGLT2i组尿路感染风险与DPP4i组无显著差异(HR 0.90,95%CI 0.79-1.03)。
- SGLT2i组糖尿病酮症酸中毒风险与DPP4i组无显著差异(HR 1.07,95%CI 0.53-2.14),骨折风险无显著差异(HR 0.95,95%CI 0.66-1.36)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Patients with systemic lupus erythematosus (SLE) were excluded from sodium-glucose cotransporter 2 inhibitors (SGLT2i) clinical trials. It is unknown whether the cardiorenal benefits of SGLT2i extend to patients with SLE and comorbid type 2 diabetes (T2D). METHODS: We performed an emulated clinical trial in an insurance-based cohort in the United States, evaluating SGLT2i versus dipeptidyl peptidase-4 inhibitors (DPP4i) for primary prevention of cardiovascular, renal, and other clinical outcomes among patients with both SLE and comorbid T2D. SGLT2i initiators were matched to DPP4i initiators using propensity scores (PSs) based on clinical and demographic factors. Hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated using Cox models. RESULTS: Outcomes among 2,165 patients starting SGLT2i and 2,165 PS-matched patients starting DPP4i were compared. Over 753.1 (±479.2) mean days, SGLT2i recipients had significantly lower risks of incident acute kidney injury (HR 0.49, 95% CI 0.39-0.63), chronic kidney disease (HR 0.61, 95% CI 0.50-0.76), end-stage renal disease (HR 0.40, 95% CI 0.20-0.80), heart failure (HR 0.72, 95% CI 0.56-0.92), emergency department visits (HR 0.90, 0.82-0.99), and severe sepsis (HR 0.61, 95% CI 0.39-0.94). Risks of all-cause mortality (HR 0.89, 95% CI 0.65-1.21), lupus nephritis (HR 0.67, 95% CI 0.38-1.15), myocardial infarction (HR 0.81, 95% CI 0.54-1.23), stroke (HR 1.03, 95% CI 0.74-1.44), and hospitalizations (HR 0.76, 95% CI 0.51-1.12) did not differ. Genital infection risk (HR 1.31, 95% CI 1.07-1.61) was increased, but urinary tract infection risk (HR 0.90, 95% CI 0.79-1.03) did not differ. No significant difference was observed for diabetic ketoacidosis risk (HR 1.07, 95% CI 0.53-2.14) and fractures (HR 0.95, 95% CI 0.66-1.36). CONCLUSION: In this emulated clinical trial, treatment with SGLT2i, compared to DPP4i therapy, was associated with significantly reduced risks of several cardiorenal complications among patients with both SLE and T2D.
引用
- Ma KS, Lo JE, Kyttaris VC, et al. Efficacy and Safety of Sodium-Glucose Cotransporter 2 Inhibitors for the Primary Prevention of Cardiovascular, Renal Events, and Safety Outcomes in Patients With Systemic Lupus Erythematosus and Comorbid Type 2 Diabetes: A Population-Based Target Trial Emulation. Arthritis Rheumatol. 2024. PMID: 39431397. doi:10.1002/art.43037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。